ESPR Average Annual Return 10 Years
ESPR Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into ESPR

Also see:
• ESPR stock yearly return 2016
• ESPR stock yearly return 2017
• ESPR stock yearly return 2018
• ESPR stock yearly return 2019
• ESPR stock yearly return 2020
• ESPR stock yearly return 2021
• ESPR stock yearly return 2022
• ESPR stock yearly return 2023
• ESPR stock yearly return 2024
• ESPR stock yearly return 2025
• ESPR YTD return
Average Annual Return Benchmarks
Compare ESPR average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
ESPR Share Performance
ESPR Average Annual Return Table 10 Years
Start date: 04/20/2016
End date: 04/17/2026
Start price/share: $18.32
End price/share: $2.04
Dividends collected/share: $0.00
Total return: -88.86%
ESPR Average Annual Return: -19.71%
Starting investment: $10,000.00
Ending investment: $1,113.98
Years: 10.00


ESPR average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Esperion Therapeutics Inc (New)
Esperion Therapeutics, Inc. is a pharmaceutical company. Co. is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Co.'s NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). The ESPR average annual return 10 years is shown above.

The Average Annual Return on the ESPR average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether ESPR average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the ESPR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
ESPR Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree ESPR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Esperion Therapeutics (ESPR) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

ETON Average Annual Return
EVFM Average Annual Return
EW Average Annual Return
EWTX Average Annual Return
EXEL Average Annual Return
EYE Average Annual Return
EYEG Average Annual Return
EYPT Average Annual Return
FATE Average Annual Return
FBIO Average Annual Return
More Healthcare companies »
What has the average annual return been for ESPR over the past ten years?
✔️Accepted answer: The ten year ESPR average annual return has been -19.71%.

What start date was used in your ESPR average annual return calculation?
✔️Accepted answer: The start date was 04/20/2016.

What end date was used in your ESPR average annual return calculation?
✔️Accepted answer: The end date was 04/17/2026.

If I had invested $10,000 into ESPR ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 04/17/2026, you would have $1,113.98.

What does that work out to on a total return basis?
✔️Accepted answer: The ESPR ten year total return ending 04/17/2026 works out to -88.86%.


Also see:
• ESPR stock yearly return 2016
• ESPR stock yearly return 2017
• ESPR stock yearly return 2018
• ESPR stock yearly return 2019
• ESPR stock yearly return 2020
• ESPR stock yearly return 2021
• ESPR stock yearly return 2022
• ESPR stock yearly return 2023
• ESPR stock yearly return 2024
• ESPR stock yearly return 2025
• ESPR YTD return
 

ESPR Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.